Adolescents with acute lymphoblastic leukaemia: Outcome on UK National Paediatric (ALL97) and adult (UKALLXII/E2993) trials

Pediatric Blood and Cancer

Volumn 48, Issue 3, 2007, Pages 254-261

  Ramanujachar, Ramya ^a   Richards, Sue ^b   Hann, Ian ^a,c   Goldstone, Anthony ^d   Mitchell, Christopher ^e   Vora, Ajay ^f   Rowe, Jacob ^g   Webb, David ^c  

^a UNIVERSITY COLLEGE LONDON   (United Kingdom)

^b CLINICAL TRIAL SERVICE UNIT   (United Kingdom)

^c GREAT ORMOND STREET HOSPITAL   (United Kingdom)

^d UNIVERSITY COLLEGE HOSPITAL   (United Kingdom)

^e JOHN RADCLIFFE HOSPITAL   (United Kingdom)

^f SHEFFIELD CHILDREN S HOSPITAL   (United Kingdom)

^g RAMBAM MEDICAL CENTER   (Israel)

Author keywords

Acute lymphoblastic leukemia; Adolescent; Survival; Treatment outcome; Young adult

Indexed keywords

ASPARAGINASE; CYCLOPHOSPHAMIDE; CYTARABINE; DAUNORUBICIN; DEXAMETHASONE; ETOPOSIDE; MERCAPTOPURINE; METHOTREXATE; PREDNISOLONE; TIOGUANINE; VINCRISTINE;

ACUTE LYMPHOBLASTIC LEUKEMIA; ADOLESCENT; ALLOGENIC BONE MARROW TRANSPLANTATION; ARTICLE; CANCER RADIOTHERAPY; CANCER SURVIVAL; CLINICAL PROTOCOL; CLINICAL TRIAL; COMBINATION CHEMOTHERAPY; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DRUG MEGADOSE; FEMALE; HUMAN; MAJOR CLINICAL STUDY; MALE; MULTIPLE CYCLE TREATMENT; OUTCOME ASSESSMENT; PATIENT REFERRAL; PHILADELPHIA 1 CHROMOSOME; PRIORITY JOURNAL; RETROSPECTIVE STUDY; UNITED KINGDOM;

6-MERCAPTOPURINE; ADOLESCENT; AGE FACTORS; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; ASPARAGINASE; BONE MARROW TRANSPLANTATION; COMBINED MODALITY THERAPY; CRANIAL IRRADIATION; CYCLOPHOSPHAMIDE; CYTARABINE; DAUNORUBICIN; DEXAMETHASONE; DISEASE-FREE SURVIVAL; ETOPOSIDE; FEMALE; HUMANS; LEUKEMIA, LYMPHOCYTIC, ACUTE; MALE; METHOTREXATE; PATIENT SELECTION; PREDNISOLONE; PROGNOSIS; RANDOMIZED CONTROLLED TRIALS; REMISSION INDUCTION; RESEARCH DESIGN; SURVIVAL ANALYSIS; THIOGUANINE; TRANSPLANTATION, AUTOLOGOUS; TRANSPLANTATION, HOMOLOGOUS; TREATMENT OUTCOME; VINCRISTINE;

EID: 33846908289     PISSN: 15455009     EISSN: 15455017     Source Type: Journal    
DOI: 10.1002/pbc.20749     Document Type: Article

References (39)

1. Chessells JM, Hall E, Prentice HG, et al. The impact of age on outcome in lymphoblastic leukaemia; MRC UKALL X and XA compared: A report from the MRC Paediatric and Adult Working Parties. Leukemia 1998;12:463-473.
2. Schrappe M, Reiter A, Ludwig WD, et al. Improved outcome in childhood acute lymphoblastic leukemia despite reduced use of anthracyclines and cranial radiotherapy: Results of trial ALL-BFM 90. German-Austrian-Swiss ALL-BFM Study Group. Blood 2000;95:3310-3322.
3. Gaynon PS, Trigg ME, Heerema NA, et al. Children's Cancer Group trials in childhood acute lymphoblastic leukemia: 1983-1995. Leukemia 2000;14:2223-2233.
4. Nachman J, Sather HN, Buckley JD, et al. Young adults 16-21 years of age at diagnosis entered on childrens cancer group acute lymphoblastic leukemia and acute myeloblastic leukemia protocols. Results of treatment. Cancer 1993;71:3377-3385.
5. Hann I, Vora A, Richards S, et al. Benefit of intensified treatment for all children with acute lymphoblastic leukaemia: Results from MRC UKALL XI and MRC ALL97 randomised trials. UK Medical Research Council's Working Party on childhood leukaemia. Leukemia 2000;14:356-363.
6. Mitchell CD, Richards SM, Kinsey SE, et al. Benefit of dexamethasone compared with prednisolone for childhood acute lymphoblastic leukaemia: Results of the UK Medical Research Council ALL97 randomized trial. Br J Haematol 2005;129:734-745.
7. Durrant IJ, Richards SM, Prentice HG, et al. The Medical Research Council trials in adult acute lymphocytic leukemia. Hematol Oncol Clin North Am 2000;14:1327-1352.
8. Hann I, Vora A, Harrison G, et al. Determinants of outcome after intensified therapy of childhood lymphoblastic leukaemia: Results from Medical Research Council United Kingdom acute lymphoblastic leukaemia XI protocol. Br J Haematol 2001;113:103-114.
9. Hill JM, Kornblith AB, Jones D, et al. A comparative study of the long term psychosocial functioning of childhood acute lymphoblastic leukemia survivors treated by intrathecal methotrexate with or without cranial radiation. Cancer 1998;82:208-218.
10. Schrappe M, Camitta B, Pui CH, et al. Long-term results of large prospective trials in childhood acute lymphoblastic leukemia. Leukemia 2000;14:2193-2194.
11. Bostrom BC, Sensel MR, Sather HN, et al. Dexamethasone versus prednisone and daily oral versus weekly intravenous mercaptopurine for patients with standard-risk acute lymphoblastic leukemia: A report from the Children's Cancer Group. Blood 2003;101:3809-3817.
12. Kaplan E, Meier P. Nonparametric estimation from incomplete observations. J Am Stat Assoc 1958;53:457-481.
13. Mantel N. Evaluation of survival data and two new rank order statistics arising in its consideration. Cancer Chemother Rep 1966;50:163-170.
14. Cox DR. Regression models and life tables. J R Stat Soc 1972;34:187-220.
15. Conter V, Arico M, Valsecchi MG, et al. Long-term results of the Italian Association of Pediatric Hematology and Oncology (AIEOP) acute lymphoblastic leukemia studies, 1982-1995. Leukemia 2000;14:2196-2204.
16. Schrappe M, Reiter A, Zimmermann M, et al. Long-term results of four consecutive trials in childhood ALL performed by the ALL-BFM Study Group from 1981 to 1995. Berlin-Frankfurt-Munster. Leukemia 2000;14:2205-2222.
17. Harms DO, Janka-Schaub GE. Co-operative study group for childhood acute lymphoblastic leukemia (COALL): Long-term follow-up of trials 82, 85, 89 and 92. Leukemia 2000;14:2234-2239.
18. Silverman LB, Declerck L, Gelber RD, et al. Results of Dana-Farber Cancer Institute Consortium protocols for children with newly diagnosed acute lymphoblastic leukemia (1981-1995). Leukemia 2000;14:2247-2256.
19. Vilmer E, Suciu S, Ferster A, et al. Long-term results of three randomized trials (58831, 58832, 58881) in childhood acute lymphoblastic leukemia: A CLCG-EORTC report. Children leukemia cooperative group. Leukemia 2000;14:2257-2266.
20. Pui CH, Boyett JM, Rivera GK, et al. Long-term results of Total Therapy Studies 11, 12 and 13a for childhood acute lymphoblastic leukemia at St. Jude Children's Research Hospital. Leukemia 2000;14:2286-2294.
21. Fiere D, Schaison G, Bancillon A, et al. What is the best treatment for patients between 15 years and 20 years with acute lymphoblastic leukemia? Comparative results of two protocols, on for adults, one for children. Blood 1990;76:270a.
22. Boissel N, Auclerc MF, Lheritier V, et al. Should adolescents with acute lymphoblastic leukemia be treated as old children or young adults? Comparison of the French FRALLE-93 and LALA-94 trials. J Clin Oncol 2003;21:774-780.
23. Testi AM, Valsecch MG. Differences in outcome of adolescents with acute lymphoblastic leukemia enrolled in paediatric (AIEOP) and adult (GIMEMA) protocols. Blood 2004;104:1954a.
24. Stock WSH, Dodge RK. Outcome of adolescents and young adults with ALL: A comparison of Children's Cancer Group (CCG) and Cancer and Leukaemia Group B (CALGB) regimens. Blood 2000;96:467a.
25. de Bont JM, Holt B, Dekker AW, et al. Significant difference in outcome for adolescents with acute lymphoblastic leukemia treated on pediatric vs adult protocols in the Netherlands. Leukemia 2004;18:2032-2035.
26. Annino L, Vegna ML, Camera A, et al. Treatment of adult acute lymphoblastic leukemia (ALL): Long-term follow-up of the GIMEMA ALL 0288 randomized study. Blood 2002;99:863-871.
27. Hoelzer D, Thiel E, Ludwig WD, et al. Follow-up of the first two successive German multicentre trials for adult ALL (01/81 and 02/84). German adult ALL study group. Leukemia 1993;7:S130-S134.
28. Hussein KK, Dahlberg S, Head D, et al. Treatment of acute lymphoblastic leukemia in adults with intensive induction, consolidation, and maintenance chemotherapy. Blood 1989;73:57-63.
29. Group CAC. Duration and intensity of maintenance chemotherapy in acute lymphoblastic leukaemia: Overview of 42 trials involving 12,000 randomised children. Childhood ALL Collaborative Group. Lancet 1996;347:1783-1788.
30. Burger B, Beier R, Zimmermann M, et al. Osteonecrosis: A treatment related toxicity in childhood acute lymphoblastic leukemia (ALL)-experiences from trial ALL-BFM 95. Pediatr Blood Cancer 2005;44:220-225.
31. Mattano LA, Jr., Sather HN, Trigg ME, et al. Osteonecrosis as a complication of treating acute lymphoblastic leukemia in children: A report from the Children's Cancer Group. J Clin Oncol 2000;18:3262-3272.
32. Strauss AJ, Su JT, Dalton VM, et al. Bony morbidity in children treated for acute lymphoblastic leukemia. J Clin Oncol 2001;19:3066-3072.
33. Rubnitz JE, Lensing S, Zhou Y, et al. Death during induction therapy and first remission of acute leukemia in childhood: The St. Jude experience. Cancer 2004;101:1677-1684.
34. Larson RA, Dodge RK, Burns CP, et al. A five-drug remission induction regimen with intensive consolidation for adults with acute lymphoblastic leukemia: Cancer and Leukemia Group B study 8811. Blood 1995;85:2025-2037.
35. Petersdorf SH, Kopecky KJ, Head DR, et al. Comparison of the L10M consolidation regimen to an alternative regimen including escalating methotrexate/L-asparaginase for adult acute lymphoblastic leukemia: A Southwest Oncology Group Study. Leukemia 2001;15:208-216.
36. Arico M, Valsecchi MG, Camitta B, et al. Outcome of treatment in children with Philadelphia chromosome-positive acute lymphoblastic leukemia. N Engl J Med 2000;342:998-1006.
37. Jeha S. Who should be treating adolescents and young adults with acute lymphoblastic leukaemia? Eur J Cancer 2003;39:2579-2583.
38. Schiffer CA. Differences in outcome in adolescents with acute lymphoblastic leukemia: A consequence of better regimens? Better doctors? Both? J Clin Oncol 2003;21:760-761.
39. Reynolds BC, Windebank KP, Leonard RC, et al. A comparison of self-reported satisfaction between adolescents treated in a "teenage" unit with those treated in adult or paediatric units. Pediatr Blood Cancer 2005;44:259-263.